Abstract
Malignant melanoma represents a serious public health problem and is a deadly disease when it is diagnosed at late stage. Though 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) has been widely used clinically for melanoma imaging, other approaches to specifically identify, characterize, monitor and guide therapeutics for malignant melanoma are still needed. Consequently, many probes targeting general molecular events including metabolism, angiogenesis, hypoxia and apoptosis in melanoma have been successfully developed. Furthermore, probes targeting melanoma associated targets such as melanocortin receptor 1 (MC1R), melanin, etc. have undergone active investigation and have demonstrated high melanoma specificity. In this review, these molecular probes targeting diverse melanoma biomarkers have been summarized. Some of them may eventually contribute to the improvement of personalized management of malignant melanoma.
Keywords: Molecular Imaging, Melanoma, PET, Molecular Probe, MC1R, Melanin
Current Pharmaceutical Biotechnology
Title: Molecular Probes for Malignant Melanoma Imaging
Volume: 11 Issue: 6
Author(s): Gang Ren, Ying Pan and Zhen Cheng
Affiliation:
Keywords: Molecular Imaging, Melanoma, PET, Molecular Probe, MC1R, Melanin
Abstract: Malignant melanoma represents a serious public health problem and is a deadly disease when it is diagnosed at late stage. Though 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) has been widely used clinically for melanoma imaging, other approaches to specifically identify, characterize, monitor and guide therapeutics for malignant melanoma are still needed. Consequently, many probes targeting general molecular events including metabolism, angiogenesis, hypoxia and apoptosis in melanoma have been successfully developed. Furthermore, probes targeting melanoma associated targets such as melanocortin receptor 1 (MC1R), melanin, etc. have undergone active investigation and have demonstrated high melanoma specificity. In this review, these molecular probes targeting diverse melanoma biomarkers have been summarized. Some of them may eventually contribute to the improvement of personalized management of malignant melanoma.
Export Options
About this article
Cite this article as:
Ren Gang, Pan Ying and Cheng Zhen, Molecular Probes for Malignant Melanoma Imaging, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246465
DOI https://dx.doi.org/10.2174/138920110792246465 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy Emerging Drugs for the Treatment of Cancer Pain: A Review of Patent Literature in 2014
Recent Patents on Anti-Cancer Drug Discovery Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives
Current Medicinal Chemistry Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
Current Gene Therapy Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology Nitrite-stimulated Gastric Formation of S-nitrosothiols As An Antihypertensive Therapeutic Strategy
Current Drug Targets Quantitative Proteomics Profiling of RKO and HT29 Cell Lines by iTRAQ Coupled LC-MS/MS
Current Proteomics Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design The Reciprocal Interaction: Chemotherapy and Tumor Microenvironment
Current Drug Discovery Technologies Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Letters in Drug Design & Discovery